Abbott Laboratories (NYSE:ABT) Updates Q2 2025 Earnings Guidance

Abbott Laboratories (NYSE:ABT - Get Free Report) issued an update on its second quarter 2025 earnings guidance on Wednesday morning. The company provided EPS guidance of 1.230-1.270 for the period, compared to the consensus EPS estimate of 1.250. The company issued revenue guidance of -. Abbott Laboratories also updated its FY 2025 guidance to 5.050-5.250 EPS.

Wall Street Analyst Weigh In

ABT has been the subject of several recent research reports. Stifel Nicolaus upped their price target on shares of Abbott Laboratories from $135.00 to $145.00 and gave the company a "buy" rating in a research report on Thursday. Jefferies Financial Group increased their price objective on Abbott Laboratories from $135.00 to $137.00 and gave the company a "hold" rating in a report on Thursday. Evercore ISI upped their price target on Abbott Laboratories to $136.00 and gave the company a "buy" rating in a research report on Thursday, January 2nd. Wells Fargo & Company raised their price objective on Abbott Laboratories from $136.00 to $147.00 and gave the stock an "overweight" rating in a research report on Thursday. Finally, Bank of America upped their target price on Abbott Laboratories from $133.00 to $150.00 and gave the company a "buy" rating in a report on Monday, March 10th. Four analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Abbott Laboratories presently has an average rating of "Moderate Buy" and an average price target of $142.59.

Abbott Laboratories Stock Down 1.4 %

Abbott Laboratories stock traded down $1.80 during mid-day trading on Monday, reaching $129.18. The stock had a trading volume of 1,758,612 shares, compared to its average volume of 6,010,206. The firm has a market capitalization of $224.04 billion, a PE ratio of 16.89, a price-to-earnings-growth ratio of 2.52 and a beta of 0.80. The stock's 50-day simple moving average is $130.62 and its 200-day simple moving average is $121.96. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.14 and a current ratio of 1.60. Abbott Laboratories has a fifty-two week low of $99.71 and a fifty-two week high of $141.23.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its earnings results on Wednesday, April 16th. The healthcare product maker reported $1.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.07 by $0.02. Abbott Laboratories had a return on equity of 20.74% and a net margin of 31.95%. The company had revenue of $10.36 billion for the quarter, compared to analysts' expectations of $10.38 billion. On average, sell-side analysts forecast that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, May 15th. Stockholders of record on Tuesday, April 15th will be given a dividend of $0.59 per share. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.83%. The ex-dividend date is Tuesday, April 15th. Abbott Laboratories's dividend payout ratio is currently 30.61%.

Insider Activity

In other news, EVP Daniel Gesua Sive Salvadori sold 23,771 shares of the business's stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $128.50, for a total transaction of $3,054,573.50. Following the completion of the transaction, the executive vice president now directly owns 125,697 shares in the company, valued at $16,152,064.50. The trade was a 15.90 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Lisa D. Earnhardt sold 91,167 shares of the firm's stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $133.82, for a total value of $12,199,967.94. Following the completion of the sale, the executive vice president now directly owns 71,928 shares in the company, valued at approximately $9,625,404.96. The trade was a 55.90 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 116,449 shares of company stock valued at $15,463,316 in the last 90 days. Insiders own 0.46% of the company's stock.

Hedge Funds Weigh In On Abbott Laboratories

An institutional investor recently raised its position in Abbott Laboratories stock. Brighton Jones LLC lifted its stake in Abbott Laboratories (NYSE:ABT - Free Report) by 10.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 51,719 shares of the healthcare product maker's stock after buying an additional 4,755 shares during the period. Brighton Jones LLC's holdings in Abbott Laboratories were worth $5,850,000 as of its most recent SEC filing. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.